ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2616

Mesenchymal Stem Cells Induce CD1c+ Tolerogenic Dendritic Cells Via up-Regulating FLT3L in Systemic Lupus Erythematosus

Xinran Yuan1, Dandan Wang2 and Lingyun Sun3, 1Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 2Department of Rheumatology and immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 3Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital, Nanjing University Medical School, nanjing, China

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Dendritic cells, Mesenchymal stem cells and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Several tolerogenic dendritic cell (DC) subsets have been identified in human such as CD1c+ DCs, which could be elevated by injection of Flt-3 ligand (FLT3L). CD1c+ tolerogenic DCs play important roles in the induction of peripheral tolerance and control of adaptive immune response, hence, they have become appealing targets in the treatment of systemic lupus erythematosus (SLE). Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) also exhibit immunoregulatory effects in SLE. However, the underlying immunosuppression mechanism of MSCs via tolerogenic DCs in SLE remains largely unknown. The aim of this study is to examine tolerogenic DCs levels in SLE patients, and to further investigate the mechanism of MSCs in the regulation of tolerogenic DCs.

Methods: Tolerogenic DCs were isolated as Lin(CD3/19/56/14)– HLA DR+CD11c+CD1c+ from peripheral blood mononuclear cells (PBMCs). Level of tolerogenic DCs was determined by flow cytometry, and serum concentration of FLT3L was assessed by ELISA from 17 healthy controls and 25 SLE patients. Eight SLE patients were given UC MSCs infusions. We compared the levels of tolerogenic DCs and serum FLT3L before and 24 hours after UC MSCs transplantation. PBMCs from 8 patients were collected and co-cultured with UC MSCs at ratios of 1:1, 10:1 and 50:1, for 24 hours, 48 hours and 72 hours, respectively, to detect the level of tolerogenic DCs. The level of FLT3L in the supernatant solution was analyzed. FLT3L siRNA was added to the co-culture system, and the level of tolerogenic DCs was detected.

Results: The levels of peripheral CD1c+ DCs and serum FLT3L were significantly decreased in SLE patients compared to healthy controls. Moreover, the level of CD1c+ DCs was remarkably negatively correlated with SLE disease activity index (SLEDAI) scores. After UC MSCs transplantation, the level of CD1c+ DCs increased, along with an increase in serum FLT3L. In vitro studies showed that UC MSCs time-dependently up-regulated peripheral CD1c+ DCs, but not dose-dependently. The supernatant FLT3L level significantly increased after co-cultured with MSCs. However, the addition of FLT3L siRNA significantly abrogated the up-regulation of CD1c+ DCs by MSCs, which could be reversed by adding extra FLT3L to the co-culture system.

Conclusion: UC MSCs induce CD1c+ tolerogenic DCs through up-regulating FLT3L in lupus patients.


Disclosure: X. Yuan, None; D. Wang, None; L. Sun, None.

To cite this abstract in AMA style:

Yuan X, Wang D, Sun L. Mesenchymal Stem Cells Induce CD1c+ Tolerogenic Dendritic Cells Via up-Regulating FLT3L in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/mesenchymal-stem-cells-induce-cd1c-tolerogenic-dendritic-cells-via-up-regulating-flt3l-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mesenchymal-stem-cells-induce-cd1c-tolerogenic-dendritic-cells-via-up-regulating-flt3l-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology